Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
| Ano de defesa: | 2024 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | |
| Tipo de documento: | Dissertação |
| Tipo de acesso: | Acesso aberto |
| Idioma: | por |
| Instituição de defesa: |
Universidade Federal da Paraíba
Brasil Farmacologia Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos UFPB |
| Programa de Pós-Graduação: |
Não Informado pela instituição
|
| Departamento: |
Não Informado pela instituição
|
| País: |
Não Informado pela instituição
|
| Palavras-chave em Português: | |
| Link de acesso: | https://repositorio.ufpb.br/jspui/handle/123456789/31946 |
Resumo: | Microorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays. |
| id |
UFPB-2_900ec6bc57514189ff8f494e99cb3ffb |
|---|---|
| oai_identifier_str |
oai:repositorio.ufpb.br:123456789/31946 |
| network_acronym_str |
UFPB-2 |
| network_name_str |
Repositório Institucional da UFPB |
| repository_id_str |
|
| spelling |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentesFungicidasCandida spp.BiofilmeAtividade antifúngicaResistência fúngicaFungicidesBiofilmAntifungal activityFungal resistanceCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAMicroorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays.Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESOs microrganismos do gênero Candida são responsáveis por muitas entidades clínicas, envolvendo desde micoses localizadas a exemplo das onicomicoses, candidíases bucais e vulvovaginais a micoses sistêmicas como a candidíase disseminada. As espécies do gênero Candida estão entre os principais agentes responsáveis por óbitos cuja causa seja a infecção por fungos e merecem destaque Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) e Candida parapsilosis. Tais microrganismos também são lembrados por sua notável capacidade de resistência às drogas antifúngicas através de diversos mecanismos, a saber: vias metabólicas alternativas, formação de biofilmes, mutações nos genes para síntese de ergosterol e superexpressão de bombas de efluxo. A busca por novas moléculas antifúngicas sintéticas constitui-se como uma alternativa terapêutica neste cenário dada a possibilidade da descoberta de novas classes farmacológicas ou de novos esquemas de terapia combinada com os antifúngicos clássicos. Neste estudo foi investigado através de diferentes ensaios o perfil antifúngico de uma amida sintética, a 2-bromo-N-fenilacetamida, frente às espécies C. albicans, C. tropicalis, N. glabratus (C. glabrata) e C. parapsilosis. A molécula 2-bromo-N-fenilacetamida (“A1Br”) exibiu atividade fungicida, com Concentração Inibitória Mínima (CIM) de 32 μg.mL-1 para 87,5% das cepas testadas e Concentração Fungicida Mínima (CFM) de 64 μg.mL-1 para 81,25% dos microrganismos. Também se mostrou um potente agente contra biofilmes maduros de C. albicans, cuja redução variou de 59-80%, estatisticamente tão significativa quanto a da anfotericina B (redução de 32-83%) na comparação de cada um desses tratamentos em relação ao grupo controle. Já quando associada aos antifúngicos licenciados fluconazol e anfotericina B a molécula “A1Br” exibiu efeitos indiferentes. Seu mecanismo de ação permanece passível de esclarecimento uma vez que não foram observadas alterações na sua CIM nos ensaios de sorbitol e ergosterol.Universidade Federal da ParaíbaBrasilFarmacologiaPrograma de Pós-Graduação em Produtos Naturais e Sintéticos BioativosUFPBLima, Edeltrudes de Oliveirahttp://lattes.cnpq.br/9406572870167006Teixeira, Bráulio de Almeida2024-09-20T10:36:49Z2024-04-052024-09-20T10:36:49Z2024-02-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/31946porAttribution-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2024-09-21T06:06:29Zoai:repositorio.ufpb.br:123456789/31946Repositório InstitucionalPUBhttps://repositorio.ufpb.br/oai/requestdiretoria@ufpb.br||bdtd@biblioteca.ufpb.bropendoar:25462024-09-21T06:06:29Repositório Institucional da UFPB - Universidade Federal da Paraíba (UFPB)false |
| dc.title.none.fl_str_mv |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| title |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| spellingShingle |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes Teixeira, Bráulio de Almeida Fungicidas Candida spp. Biofilme Atividade antifúngica Resistência fúngica Fungicides Biofilm Antifungal activity Fungal resistance CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
| title_short |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| title_full |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| title_fullStr |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| title_full_unstemmed |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| title_sort |
Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes |
| author |
Teixeira, Bráulio de Almeida |
| author_facet |
Teixeira, Bráulio de Almeida |
| author_role |
author |
| dc.contributor.none.fl_str_mv |
Lima, Edeltrudes de Oliveira http://lattes.cnpq.br/9406572870167006 |
| dc.contributor.author.fl_str_mv |
Teixeira, Bráulio de Almeida |
| dc.subject.por.fl_str_mv |
Fungicidas Candida spp. Biofilme Atividade antifúngica Resistência fúngica Fungicides Biofilm Antifungal activity Fungal resistance CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
| topic |
Fungicidas Candida spp. Biofilme Atividade antifúngica Resistência fúngica Fungicides Biofilm Antifungal activity Fungal resistance CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
| description |
Microorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-09-20T10:36:49Z 2024-04-05 2024-09-20T10:36:49Z 2024-02-23 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| format |
masterThesis |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://repositorio.ufpb.br/jspui/handle/123456789/31946 |
| url |
https://repositorio.ufpb.br/jspui/handle/123456789/31946 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Farmacologia Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos UFPB |
| publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Farmacologia Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos UFPB |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFPB instname:Universidade Federal da Paraíba (UFPB) instacron:UFPB |
| instname_str |
Universidade Federal da Paraíba (UFPB) |
| instacron_str |
UFPB |
| institution |
UFPB |
| reponame_str |
Repositório Institucional da UFPB |
| collection |
Repositório Institucional da UFPB |
| repository.name.fl_str_mv |
Repositório Institucional da UFPB - Universidade Federal da Paraíba (UFPB) |
| repository.mail.fl_str_mv |
diretoria@ufpb.br||bdtd@biblioteca.ufpb.br |
| _version_ |
1863379084710510592 |